Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01HDD
|
|||
| Former ID |
DNC007984
|
|||
| Drug Name |
2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione
|
|||
| Synonyms |
CHEMBL11516; 63586-13-0; 2-Benzyl-4,5,6,7-tetrachloro-isoindole-1,3-dione; 2-benzyl-4,5,6,7-tetrachloro-1H-isoindole-1,3(2H)-dione; AC1LK1ZO; Oprea1_023833; 2-benzyl-4,5,6,7-tetrachloroisoindole-1,3-dione; 2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione; SCHEMBL10675358; CTK2A8819; DTXSID60359687; MolPort-001-020-850; ZINC630019; STK246502; BDBM50088678; AKOS003243470; MCULE-7798575308; N-Benzyl-3,4,5,6-tetrachlorophthalimide; ST50854964; AK-918/11423009; 4,5,6,7-tetrachloro-2-benzylbenzo[c]azolidine-1,3-dione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H7Cl4NO2
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)CN2C(=O)C3=C(C2=O)C(=C(C(=C3Cl)Cl)Cl)Cl
|
|||
| InChI |
1S/C15H7Cl4NO2/c16-10-8-9(11(17)13(19)12(10)18)15(22)20(14(8)21)6-7-4-2-1-3-5-7/h1-5H,6H2
|
|||
| InChIKey |
MQFQHWBPMPPVNJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 63586-13-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxysterols receptor LXR-alpha (NR1H3) | Target Info | Inhibitor | [1] |
| Oxysterols receptor LXR-beta (NR1H2) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | PPAR signaling pathway | |||
| Non-alcoholic fatty liver disease (NAFLD) | ||||
| Hepatitis C | ||||
| Pathway Interaction Database | RXR and RAR heterodimerization with other nuclear receptor | |||
| Reactome | Nuclear Receptor transcription pathway | |||
| WikiPathways | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| Nuclear Receptors Meta-Pathway | ||||
| PPAR Alpha Pathway | ||||
| Liver X Receptor Pathway | ||||
| Adipogenesis | ||||
| SREBF and miR33 in cholesterol and lipid homeostasis | ||||
| Nuclear Receptors | ||||
| SREBP signalling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.